On March 28th, Fosun International Chairman Guo Guangchang said at the 2023 annual results conference, “We are even more clear that we must focus on building sustainable, predictable, and enterprise with stable profit growth. Our core strategy revolves around directing our efforts towards enterprises where we have already established advantages. We used to “p

“We are even more clear that we must focus on building sustainable, predictable, and enterprise with stable growth. ”Speaking at the 2023 annual results conferenceon March 28th, Fosun International Chairman Guo Guangchang said, “We are even more clear that we must focus on building sustainable, predictable, and enterprise with stable profit growth.

(Hong Kong, Shanghai, 27 March 2024) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), today announced its annual results for the year ended 31 December 2023 (the “Reporting Period”).During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion&#x

Dear shareholders,In 2023, the global economy showed signs of recovery, yetstillfilled with challenges. The entire team of Fosun worked together, actively seized opportunities and insisted on pursuing sustainable growth, resulting in the overall achievement of steady growth.As a global innovation-driven consumer group, the Group always adheres to the strategy

Results Highlights• Business Volume1reached RMB18,125.1 million, with a year-on-year growth of 19%, surpassing the 28% recorded in 2019, while revenue increased by 24% year-on-year to RMB17,151.8 million•Profit attributable to equity holders turned around to RMB307.2 million• Club Med achieved a Business Volume of RMB15,122.5 million, representing a 19% year-on-

Recently, an Innovation Passport designation has been awarded to serplulimab, Henlius’self-developed anti-PD-1 mAb (trade name in China: HANSIZHUANG), for the treatment of extensive stage small cell lung cancer (ES-SCLC) by the U.K. Innovative Licensing and Access Pathway Steering Group including the Medicines & Healthcare products Regulatory Agency (MHRA). This design

Shanghai, China, Mar 12th, 2024 - Shanghai Henlius Biotech, Inc. (2696.HK) announced the investigational new drug (IND) application for clinical trial of HLX6018，a novel anti-GARP/TGF-β1 monoclonal antibody (mAb) independently developed by the company, was approved by the National Medical Products Administration (NMPA) for the treatment of idiopathic pulmonary fibrosis

On 12 March, Fosun Pharma announced that its controlled subsidiaries/companies, Fuxin Shenyao, Fosun Pharma (Shenzhen) and Shanghai Rehabilitation Equity Investment Fund Management Co., Ltd., together with seven investors including Shenzhen FoF, plan to jointly establish a target fund. The proposed fund-raising size of the target fund is RMB5.0 billion,

Spring Appreciation in Yuyuan GardenRecently, the 2024 Yuyuan Garden Spring Appreciation event, hosted by the Foreign Affairs Office of Shanghai Municipal People's Government and the Huangpu District Government, and organized by Shanghai Yuyuan Tourist Mart (Group) Co., Ltd., was successfully held. The event invited consular officials from nearly 40 co